

# Jack J Chen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7023665/jack-j-chen-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

844  
citations

15  
h-index

29  
g-index

32  
ext. papers

940  
ext. citations

3.1  
avg, IF

4.49  
L-index

#	Paper	IF	Citations
31	Gagnon B. 9 Events of Instruction With Active Learning: Teaching Student Pharmacists How to Measure Blood Pressure. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 34, 407-416	1.3	2
30	Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2019</b> , 31, 188-195	2.7	9
29	Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. <i>Drugs in R and D</i> , <b>2018</b> , 18, 77-86	3.4	6
28	Reply to letter. <i>Mental Health Clinician</i> , <b>2018</b> , 8, 200-201	1.6	
27	Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. <i>Annals of Pharmacotherapy</i> , <b>2018</b> , 52, 1182-1194	2.9	15
26	Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 376, 84-90	3.2	22
25	Treatment of psychotic symptoms in patients with Parkinson disease. <i>Mental Health Clinician</i> , <b>2017</b> , 7, 262-270	1.6	17
24	RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. <i>Journal of Clinical Movement Disorders</i> , <b>2017</b> , 4, 9	2.8	12
23	OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: a Systematic Literature Review. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 109-115	2.2	14
22	Effect of exercise on motor and nonmotor symptoms of Parkinson's disease. <i>Parkinson's Disease</i> , <b>2015</b> , 2015, 586378	2.6	31
21	Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study. <i>Pharmacotherapy</i> , <b>2015</b> , 35, 681-6	5.8	13
20	Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm. <i>Tremor and Other Hyperkinetic Movements</i> , <b>2015</b> , 5, 338	2	2
19	Anxiety in Parkinson's disease: identification and management. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2014</b> , 7, 52-9	6.6	93
18	Depression in Parkinson's disease: identification and management. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 972-83	5.8	29
17	Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 304-318	5.8	36
16	Movie Review: Requiem. <i>Mental Health Clinician</i> , <b>2013</b> , 3, 273-275	1.6	
15	The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?. <i>Journal of Clinical Pharmacology</i> , <b>2012</b> , 52, 620-8	2.9	24

14	Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1487-504	3.5	118
13	Parkinson disease: A summary of recent evidence-based medicine reviews. <i>Mental Health Clinician</i> , <b>2012</b> , 2, 25-31	1.6	2
12	Pharmacologic safety concerns in Parkinson's disease: facts and insights. <i>International Journal of Neuroscience</i> , <b>2011</b> , 121 Suppl 2, 45-52	2	17
11	Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate care. <i>American Journal of Managed Care</i> , <b>2011</b> , 17 Suppl 12, S322-7	2.1	1
10	Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 1452-67	5.8	40
9	Pharmacotherapy for Parkinson's disease. <i>Pharmacotherapy</i> , <b>2007</b> , 27, 161S-173S	5.8	59
8	Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 182S-49	3.5	163
7	Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. <i>Drugs and Aging</i> , <b>2007</b> , 24, 663-80	4.7	8
6	Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. <i>American Journal of Health-System Pharmacy</i> , <b>2006</b> , 63, 915-28	2.2	39
5	Nonparkinsonism movement disorders in the elderly. <i>The Consultant Pharmacist</i> , <b>2006</b> , 21, 58-71		3
4	A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 1710-24	2.5	36
3	The white coat. <i>American Journal of Health-System Pharmacy</i> , <b>2003</b> , 60, 611	2.2	
2	Essential tremor: diagnosis and treatment. <i>Pharmacotherapy</i> , <b>2003</b> , 23, 110S-22	5.8	32
1	Cost Analysis of Pharmacy-Based Aminoglycoside Regimens: Once-Daily vs. Multiple Daily Dosing. <i>Hospital Pharmacy</i> , <b>2000</b> , 35, 950-954	1.1	